Novozymes has reported that organic sales growth for 2012 was 4% (7% DKK, 3% LCY) compared with 2011. EBIT increased by 17%, raising the EBIT margin to 24.4%. Net profit grew by 10%. Strong free cash flow before acquisitions of DKK 1,581 million (US$282 million) exceeded the outlook.
